Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

SpectraScience launched its WavSTAT optical biopsy product in Europe in 2009 and intends to introduce it to the U.S. marketplace this year.

SpectraScience , Inc. , a San Diego based medical device company, announced that Jim Hitchin, CEO, was interviewed on blogtalkradio's the "Powerful Patient," where he spoke to the host and audience about SpectraScience's optical biopsy cancer screening technologies which are FDA approved for early detection of colon and cervical cancer. SpectraScience is currently running tests for the early detection of esophageal cancer.

Hitchin said, "The advantage of the Company's technology is that it can screen in real-time and the physician gets a definitive identification of abnormal and/or precancerous tissue immediately as opposed to relying solely on the subjective diagnosis and interpretation by a physician. Currently diagnosis is subject to human error, requires significant time, and is unnecessarily expensive. By using a WavSTAT Optical Biopsy System, a doctor essentially has an unbiased, accurate, low cost pathologist in residence."

When asked about possible future applications for cancer screening, Hitchin said, "Esophageal cancer is next, and the company has plans to develop applications for Inflammatory Bowel Syndrome (IBD) and lung cancer as well."

SpectraScience launched its WavSTAT optical biopsy product in Europe in 2009 and intends to introduce it to the U.S. marketplace this year. The interview can be listened to in its entirety at http://www.blogtalkradio.com/powerful-patient under the heading "Helping doctors find the right diagnosis."

SpectraScience holds approximately 60 patents worldwide that have been issued or are pending on its WavSTAT Optical Biopsy System and LUMA Cervical Imaging Systems. These devices are used to assess tissue quickly to help determine if it is normal, pre-cancerous, or cancerous. The WavSTAT and LUMA Systems are approved by the FDA for detecting pre-cancerous and cancerous tissue in the colon and cervix, respectively. An evaluation of the WavSTAT for detection of pre-cancers in the throat ("Barrett's esophagus") is being tested.

Source: SpectraScience

You can discuss about SpectraScience and its products & services in the SpectraScience Company User Group